contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-synact-pharmas-capital-markets-day-in-stockholm-march-11

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

SynAct Pharma

SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, invites investors, analysts and media to...

<div class="mfn-preamble">SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, invites investors, analysts and media to a Capital Markets Day on Wednesday, March 11, 15:00-17:00 CET in Stockholm.</div><div class="mfn-body">SynAct is entering a transformational stage as the company expects clinical data from the company’s Phase 2b ADVANCE study in patients with newly diagnosed severe rheumatoid arthritis (RA) in Q2 and expands its development pipeline in viral-induced inflammation programs. Please join the CMD to hear about SynAct’s efforts and path forward.Agenda 15:00–15:10 Welcome and Corporate Update (Jeppe Øvlesen, CEO)15:10–16:00 Resolution Therapy: A Novel Approach in Rheumatoid Arthritis<ul><li>15:10–15:25 Professor Philip Conaghan, M.D., Director of NIHR Leeds Biomedical Research Centre</li><li>15:25–15:40 How resomelagon works and the rationale for a safe and effective therapy (Thomas Jonassen, CSO)</li><li>15:40–15:50 Market overview and deal scenario (Mads Bjerregaard, CBO)</li><li>15:50–16:00 Q&amp;A</li></ul>16:00–16:45 Resolution Therapy: A Novel Approach in Respiratory Infections<ul><li>16:00–16:15 Professor Thomas Benfield, M.D., Director of Center for Clinical Research &amp; Disruption of Infectious Diseases (CREDID), Copenhagen University Hospital – Amager and Hvidovre</li><li>16:15–16:25 Preclinical rationale, the RESPIRE trial, and beyond (Thomas Jonassen, CSO)</li><li>16:25–16:35 Market overview and deal scenario (Mads Bjerregaard, CBO)</li><li>16:35–16:45 Q&amp;A</li></ul>16:45–16:55 Financial and Business Development (Ann Kristin Led, CFO; Mads Bjerregaard, CBO)16:55–17:00 Looking ahead and end of meeting (Jeppe Øvlesen, CEO)When: March 11, 2026, from 15:00–17:00 CETLocation: Investor Studios, Hötorgsskrapan 3Address: Sveavägen 9 or Mäster Samuelsgatan 42 or Sergelgatan 8–10, Floor 7Additional information:If you enter the building via Sveavägen 9 or Sergelgatan 8–10, choose the escalator, turn to the left after entering the next floor and choose the elevator in front of you (floor 7).If you enter the building via Mäster Samuelsgatan 42, go straight ahead and pass the reception and continue towards the elevators you see in front of you (floor 7).Follow the broadcast live here:<a rel="noopener" href="https://www.youtube.com/live/aVmsHexj9KE">https://www.youtube.com/live/aVmsHexj9KE</a>The Capital Markets Day will be held in English. Presentation material will be available on SynAct’s website afterwards.Registration for the event is made by mailing investor.relations@synactpharma.com</div><div class="mfn-footer mfn-contacts mfn-f17dbb204e96">For further information, please contact: Jeppe Øvlesen CEO, SynAct Pharma AB Phone: + 45 2844 7567 E-mail: investor.relations@synactpharma.com</div><div class="mfn-footer mfn-about mfn-fae3b067917e">About SynAct Pharma AB SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information:&nbsp;<a rel="noopener" href="https://synactpharma.com/">https://synactpharma.com/</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/7edc4d16-216f-4be8-ac61-04fe9b9e11da/invitation-to-synact-pharmas-capital-markets-day-in-stockholm-march-11.pdf" class="mfn-generated mfn-primary">Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11</a></div>

Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Return on capital (ROE, ROI, ROIC, RONIC)

Balance sheet, debt leverage and risks

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up